The estimated Net Worth of Andrea Corcoran is at least $2.88 Millón dollars as of 31 January 2024. Ms Corcoran owns over 44,367 units of Atea Pharmaceuticals stock worth over $2,517,807 and over the last 4 years she sold AVIR stock worth over $0. In addition, she makes $365,000 as CFO y Exec. VP of Legal & Sec. at Atea Pharmaceuticals.
Ms has made over 1 trades of the Atea Pharmaceuticals stock since 2024, according to the Form 4 filled with the SEC. Most recently she exercised 44,367 units of AVIR stock worth $162,827 on 31 January 2024.
The largest trade she's ever made was exercising 44,367 units of Atea Pharmaceuticals stock on 31 January 2024 worth over $162,827. On average, Ms trades about 8,873 units every 0 days since 2020. As of 31 January 2024 she still owns at least 686,051 units of Atea Pharmaceuticals stock.
You can see the complete history of Ms Corcoran stock trades at the bottom of the page.
Andrea J. Corcoran is the CFO, Exec. VP of Legal & Sec. at Atea Pharmaceuticals.
As the CFO y Exec. VP of Legal & Sec. of Atea Pharmaceuticals, the total compensation of Ms Corcoran at Atea Pharmaceuticals is $365,000. There are 3 executives at Atea Pharmaceuticals getting paid more, with Dr. Jean-Pierre Sommadossi Ph.D. having the highest compensation of $902,987.
Ms Corcoran is 58, she's been the CFO y Exec. VP of Legal & Sec. of Atea Pharmaceuticals since . There are 5 older and 4 younger executives at Atea Pharmaceuticals. The oldest executive at Atea Pharmaceuticals, Inc. is Dr. Jean-Pierre Sommadossi Ph.D., 65, who is the Founder, Chairman, CEO & Pres.
Andrea's mailing address filed with the SEC is 225 FRANKLIN STREET, SUITE 2100, BOSTON, MA, 02110.
Over the last 4 years, insiders at Atea Pharmaceuticals have traded over $279,832 worth of Atea Pharmaceuticals stock and bought 553,666 units worth $13,102,824 . The most active insiders traders include Andrew A. F. Hack, Franklin M Berger y Springs Capital Management .... On average, Atea Pharmaceuticals executives and independent directors trade stock every 70 days with the average trade being worth of $229,012. The most recent stock trade was executed by Bruce Polsky on 20 June 2024, trading 17,544 units of AVIR stock currently worth $61,229.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Atea Pharmaceuticals executives and other stock owners filed with the SEC include: